Charcot-Marie-Tooth Disease clinical trials at UC Irvine
1 research study open to new patients
open to eligible people ages 18 years and up
This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with CMT1 and CMTX, to be conducted in two parts. Part 1 is non-randomized, open-label, dose-escalation and Part 2 is randomized, double-blind, and placebo-controlled.
Orange, California and other locations